Published 2026-10-28
Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test
Read the story & commentary question
Co-Diagnostics’ joint venture CoSara Diagnostics published a peer-reviewed study using the SARAGENE® HPV-HR test to screen 625 women in Central Gujarat. Twenty women tested positive for high-risk HPV; subsequent colposcopy/biopsy identified nine high-grade lesions and three invasive cervical cancers, including cases with negative cytology results.
Consider the potential role of validated molecular HPV PCR assays in expanding cervical screening strategies and lab service offerings, especially where cytology has limited sensitivity.
Consider: What laboratory validation steps and quality-control workflows are required to introduce a multiplex HPV PCR assay like SARAGENE® into routine screening programs in similar settings?
